Related Experiment Video
Updated: May 28, 2026
A Screening Method for Identification of Heterochromatin-Promoting Drugs Using Drosophila
Published on: March 12, 2020
Chemical genetics and drug screening in Drosophila cancer models
1Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, USA.
Abstract:
Drug candidates often fail in preclinical and clinical testing because of reasons of efficacy and/or safety. It would be time- and cost-efficient to have screening models that reduce the rate of such false positive candidates that appear promising at first but fail later. In this regard, it would be particularly useful to have a rapid and inexpensive whole animal model that can pre-select hits from high-throughput screens but before testing in costly rodent assays. Drosophila melanogaster has emerged as a potential whole animal model for drug screening. Of particular interest have been drugs that must act in the context of multi-cellularity such as those for neurological disorders and cancer. A recent review provides a comprehensive summary of drug screening in Drosophila, but with an emphasis on neurodegenerative disorders. Here, we review Drosophila screens in the literature aimed at cancer therapeutics.
Insights
Fruit flies offer a rapid, cost-effective model for screening potential cancer therapeutics. This approach helps identify promising drug candidates early, reducing later-stage failures in costly preclinical and clinical trials.
Area of Science:
- Pharmacology
- Genetics
- Cancer Research
Background:
- Drug development faces high failure rates due to efficacy and safety issues.
- Early identification of non-viable drug candidates is crucial for time and cost efficiency.
- Whole animal models offer advantages for screening complex, multi-cellular drug interactions.
Purpose of the Study:
- To review existing literature on drug screening using Drosophila melanogaster for cancer therapeutics.
- To highlight Drosophila as a valuable model for identifying potential cancer drugs.
- To provide a resource for researchers focused on Drosophila-based cancer drug discovery.
Main Methods:
- Systematic literature review of published Drosophila drug screening studies.
- Focus on studies targeting cancer therapeutics.
- Analysis of the utility and limitations of Drosophila models in cancer drug discovery.
Main Results:
- Drosophila melanogaster is a viable model for whole-animal drug screening.
- Numerous studies have utilized Drosophila for identifying compounds with anti-cancer activity.
- The model is particularly useful for drugs requiring multi-cellular context, relevant to cancer.
Conclusions:
- Drosophila melanogaster serves as an effective and economical model for early-stage cancer drug screening.
- Utilizing Drosophila can significantly reduce the number of false positive drug candidates entering expensive rodent assays.
- Further research and application of Drosophila models can accelerate the discovery of novel cancer therapeutics.
More Related Videos
10:31The Drosophila Imaginal Disc Tumor Model: Visualization and Quantification of Gene Expression and Tumor Invasiveness Using Genetic Mosaics
Published on: October 6, 2016
07:23A Protocol for Genetic Induction and Visualization of Benign and Invasive Tumors in Cephalic Complexes of Drosophila melanogaster
Published on: September 11, 2013
